

Corporate Medical Policy

Molecular Diagnostics for Breast Cancer Prognosis AHS - M2020

File Name: molecular_diagnostics_for_breast_cancer_prognosis
Origination: 1/2019
Last Review: 4/2024

Description of Procedure or Service

Molecular diagnostics for breast cancer management is emerging as a useful tool to aid in disease prognosis or therapeutic efficacy on an individual level. Many of the currently available molecular tests are gene expression assays that measure the number of transcribed copies of specific mRNAs to assess the genes that are active in tumor tissue, which can be clinically useful for disease classification, diagnosis, and prognosis, as well as for tailoring treatment to underlying genetic determinants of pharmacologic response (Steiling & Christenson, 2023).

Related Policies:

AHS-G2059 Epithelial Cell Cytology in Breast Cancer Risk Assessment
AHS-M2003 Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers
AHS-M2126 Use of Common Genetic Variants (Single Nucleotide Polymorphisms) To Predict Risk of Non-Familial Breast Cancer

****Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.*

Policy

BCBSNC will provide coverage for molecular diagnostics for breast cancer prognosis when it is determined the medical criteria or reimbursement guidelines below are met.

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When Molecular Diagnostics for Breast Cancer Prognosis is covered

1. For individuals with newly diagnosed breast cancer, tumor testing for hormone receptor (estrogen receptor and progesterone receptor) expression and human epidermal growth factor receptor 2 (HER2) overexpression is considered medically necessary.
2. For individuals who have been diagnosed with invasive breast cancer and who are being considered for adjuvant chemotherapy, use of the Oncotype DX 21-gene expression assay (See Note 1) is considered medically when **all** of the following criteria are also met:
 - a. Histology that is ductal/no special type (NST) (See Note 2), lobular, mixed or micropapillary.
 - b. pT1, pT2, or pT3 cancer.

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

- c. Hormone receptor (HR) positive (either estrogen-receptor [ER] or progesterone receptor [PR] positive) cancer.
 - d. Human epidermal growth factor receptor two (HER2) negative cancer.
 - e. Tumor is **one** of the following:
 - (i) pN0 tumor that is >0.5 cm in size
 - (ii) pN1mi (<2 mm axillary node metastasis)
 - (iii) pN1 (1-3 positive nodes)
3. For individuals who have been diagnosed with pT1, pT2, or operable pT3, HR positive, HER2-negative, **and** node-negative or pN1 (1-3 positive nodes) breast cancer and who have been determined to be at high clinical risk per MINDACT categorization (see Note 3), use of the MammaPrint assay is considered medically necessary.
 4. For individuals who have been diagnosed with T1 or T2, HR positive, HER2-negative, **and** node-negative or pN1 (1-3 positive nodes) breast cancer, use of the 12-gene (EndoPredict) assay **or** the 50-gene (Prosigna) assay is considered medically necessary.
 5. For individuals who have been diagnosed with T1-T3, HR-positive, HER2-negative breast cancer, use of the Breast Cancer Index (BCI) test to determine the benefit of extended adjuvant endocrine therapy is considered medically necessary.

Reimbursement for tumor testing for hormone receptor (Estrogen Receptor and Progesterone Receptor) expression and Human Epidermal Growth Factor Receptor 2 (HER2) overexpression is allowed for all women with newly diagnosed, non-metastatic breast cancer.

When Molecular Diagnostics for Breast Cancer Prognosis is not covered

1. In males, use of gene expression assays other than 21-gene RT-PCR based assays is considered investigational.
2. Use of gene expression assays not mentioned above, including but not limited to, (e.g., Mammostrat, BluePrint®) is considered investigational.
3. The use of Oncotype Dx for ductal carcinoma in situ (DCIS) is considered investigational.
4. For all other indications or in any other situation not mentioned above, use of gene expression assays is considered investigational.
5. Use of protein profiling assays (e.g., DCISionRT®, BBDRisk Dx®) is considered investigational.

NOTES

Note 1: The assay should only be ordered on a tissue specimen obtained during surgical removal of the tumor and after subsequent pathology examination of the tumor has been completed and determined to meet the above criteria (i.e., the test should not be ordered on a preliminary core biopsy without surgical staging). For patients who have multiple primary tumors, a specimen from the tumor with the most aggressive histological characteristics should be submitted for testing. It is not necessary to conduct testing on each tumor; treatment is based on the most aggressive lesion.

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

Note 2: As per NCCN Clinical Practice Guidelines in Oncology (Breast Cancer), “According to WHO, carcinoma of no special type (NST) encompasses multiple patterns including medullary pattern, cancers with neuroendocrine expression, and other rare patterns” (NCCN, 2024).

Note 3: As per NCCN Clinical Practice Guidelines in Oncology (Breast Cancer), “High clinical risk in the MINDACT trial was defined for grade 1 tumors as >3 cm N0 or T2N1, for grade 2 tumors T2N0-1, and for grade 3 tumors T1c-2N0-1” (NCCN, 2024).

Policy Guidelines

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death globally in women. Approximately one in eight women will develop breast cancer in their lifetime (Siegel, Miller, & Jemal, 2019), (Taghian, & Merajver, 2024).

While adjuvant systemic therapy has reduced mortality from breast cancer (Darby et al., 2011; Davies et al., 2011; Forouzanfar et al., 2011; Peto et al., 2012) it is not without its risks and costs: therefore reliable prognostic profiles for recurrence and clinically applicable predictive factors are of great value in the management of the disease (Foukakis & Bergh, 2022).

Several biology-based prognostic profiles have been developed, validated, and are in clinical use to predict breast cancer recurrence or response to chemotherapy. Among the most useful biomarkers for this purpose are the estrogen receptors (ER), progesterone receptors (PR), and the human epidermal growth factor receptor two (HER2). Tumors that express one or more of these proteins may have different sensitivities to certain cytotoxic chemotherapeutic agents, influencing the strategic management of the cancer. Moreover, many proprietary panels that aim to provide predictive and prognostic information about an individual’s cancer are only suitable for use in tumors of a particular type (i.e., HER2-negative). Intensive research efforts are ongoing to refine the clinical utility and the indications for these prognostic profiles (Simon et al., 2009). In addition, as next generation sequencing of tumor genomes progresses, these profiles will be improved or replaced by the next generation of molecular profiles (Foukakis & Bergh, 2022).

Chen et al. (2018) examined the association of genomic methylation and the changes in the subsequent transcriptome. The authors desired to observe how a chronic condition influenced epigenomic changes. A human volunteer provided peripheral blood samples over 36 months, and the authors created 28 methylome datasets as well as 57 transcriptome datasets. During this period, the human volunteer experienced 6 viral infections and two elevated periods of fasting glucose and glycated hemoglobin A1c. The authors noted that the methylome changes correlated with the glucose level changes, and that the gene expression levels varied greatly, often during the viral infections. The authors proposed that the DNA methylation was the primary gene expression mechanism for chronic conditions, as it was generally a stable epigenetic marker (Chen et al., 2018).

Rueda et al. (2019) presented a disease model that stratifies distinct stages and incorporated factors such as “locoregional recurrence, distant recurrence, breast-cancer-related death and death from other causes”. This model integrated these features into an individual risk-of-recurrence prediction. This model was applied to 3240 patients, of which 1980 had molecular data. From this model, the authors identified four late-recurring “integrative subtypes, comprising about one quarter (26%) of tumors that are both positive for ER and negative for human epidermal growth factor receptor 2, each with characteristic tumor-driving alterations in genomic copy number and a high risk of recurrence (mean 47–62%) up to 20 years after diagnosis”. These four subtypes were “enriched” in copy number alterations, and these alterations were labeled the “likely drivers” of each subgroup. A triple negative subgroup “IntCluster 10” was found to be largely relapse-free after five years whereas the “IntCluster4 ER negative” subgroup was found to have a large risk of recurrence (Rueda et al., 2019).

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

Innovative ideas continue to spread as the field burgeons, not limiting its inspiration to etiology. Savci-Heijink, et al., (2019) believe in the clinical value of identifying a gene expression profile in tumors that selects a subpopulation of patients that is more likely to develop visceral organ metastases due to their association with poor survival outcomes in breast cancers. The researchers analyzed the genetic profiles of 157 primary tumors from breast cancer patients who developed distant metastases and differentially expressed genes between the group of tumors with visceral metastasis and those without visceral metastases were noted. The results yielded fourteen differentially expressed genes (WDR6, CDYL, ATP6V0A4, CHAD, IDUA, MYL5, PREP, RTN4IP1, BTG2, TPRG1, ABHD14A, KIF18A, S100PBP and BEND3) between the tumors with visceral metastasis and those without visceral metastases. According to the data, five of the genes (CDYL, ATP6V0A4, PREP, RTN4IP1 and KIF18A) were upregulated while the other genes were downregulated, creating a list of biomarkers and genetic signatures of interest that may result in earlier diagnosis and treatment (Savci-Heijink et al., 2019).

Proprietary Testing

Oncotype DX

The Oncotype Dx 21-gene recurrence score (RS) is the best-validated prognostic assay and may identify patients who are most and least likely to derive benefit from adjuvant chemotherapy. The expression levels of 16 genes (plus five reference genes) are measured by quantitative reverse transcription polymerase chain reaction (RT-PCR). The sum of this calculation is known as the RS to optimize prediction of distant relapse despite tamoxifen therapy. At this time, it is indicated for women with node-negative, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer to determine the prognosis in patients recommended to proceed with at least a five-year course of endocrine therapy. The optimal RS cutoff for omission of chemotherapy remains unclear given that the different studies have used different cutoffs (Mamounas et al., 2010; Paik et al., 2004; Paik et al., 2006; Sparano et al., 2015). However, it may be reasonable not to administer adjuvant chemotherapy for patients with node-negative, ER-positive breast cancer and an RS of <15 (Foukakis & Bergh, 2022).

Sparano et al. (2018) performed a prospective trial to assess the utility of the recurrence score based on the 21 gene breast cancer assay to predict chemotherapy in patients who have a midrange score. “Of the 9719 eligible patients with follow-up information, 6711 (69%) had a midrange recurrence score of 11 to 25 and were randomly assigned to receive either chemoendocrine therapy or endocrine therapy alone. The trial was designed to show noninferiority of endocrine therapy alone for invasive disease-free survival (defined as freedom from invasive disease recurrence, second primary cancer, or death).” They found that “Endocrine therapy was noninferior to chemoendocrine therapy in the analysis of invasive disease-free survival (hazard ratio for invasive disease recurrence, second primary cancer, or death [endocrine vs. chemoendocrine therapy], 1.08; 95% confidence interval, 0.94 to 1.24; P=0.26). At nine years, the two treatment groups had similar rates of invasive disease-free survival (83.3% in the endocrine-therapy group and 84.3% in the chemoendocrine-therapy group), freedom from disease recurrence at a distant site (94.5% and 95.0%) or at a distant or local-regional site (92.2% and 92.9%), and overall survival (93.9% and 93.8%). The chemotherapy benefit for invasive disease-free survival varied with the combination of recurrence score and age (P=0.004), with some benefit of chemotherapy found in women 50 years of age or younger with a recurrence score of 16 to 25.” They concluded that “Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who had a midrange 21-gene recurrence score, although some benefit of chemotherapy was found in some women 50 years of age or younger (Sparano et al., 2018).”

In a prospective, randomized trial of endocrine therapy (ET) versus chemoendocrine therapy (CET), Kalinsky et al. (2021) attempted to gather support for the potential prognostic and predictive role of the RS for CT benefit in postmenopausal patients with 1 to 3 lymph node-positive breast cancer using Oncotype Dx in the RxPonder Trial. In the study, women with a RS less than 25 were randomized to receive ET or CET in 1:1 randomization using 3 stratification factors—RS (0-13 vs.14-25), menopausal status, and axillary nodal dissection vs. sentinel node biopsy—with the end goal of ascertaining whether the effect of CT on invasive

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

disease-free survival (IDFS) was a function of RS. Of 9383 patients screened in the study, 5083 patients were randomized based on having met eligibility criteria, and with a median follow-up period of 5.1 years, the authors observed 447 IDFS events. It was reported that in a model with CT, RS, and menopausal status (no interaction term), higher continuous RS was associated with worse IDFS (hazard ratio HR 1.06, 2-sided $p < 0$) and that CT was associated with an improvement in IDFS (HR 0.81, $p = 0.026$). Moreover, a distinction exists between postmenopausal and premenopausal patients in their reception of chemoendocrine versus endocrine therapy based on their RS: in postmenopausal patients ($n = 3350$), the HR for CET vs. ET was not significant (HR = 0.97, $p = 0.82$, indicating no benefit from CT, whereas in premenopausal patients ($N = 1665$, 33%), the HR (0.54) was statistically significant ($p = 0.0004$), suggesting CT benefit. In other words, postmenopausal patients in this situation may be spared adjuvant chemotherapy, while premenopausal patients have much to benefit from the same. Therefore, the authors concluded that “the current data show that adjuvant therapy can be de-escalated to ET alone in postmenopausal pts with a RS < 25 and 1-3 +LN” (Kalinsky et al., 2021).

Lashen et al. (2023) studied the performance of Oncotype DX compared to conventional clinicopathological parameters. The study included 420 estrogen receptor-positive/HER2-negative breast cancer patients in the United Kingdom. All patients included in the study had undergone Oncotype DX testing. The authors found a significant association between a high Oncotype DX recurrence score and grade 3 tumors, as well as a significant association between low Oncotype DX recurrence score and special tumor types. Additionally, there was an inverse association between Oncotype DX recurrence score and the levels of estrogen receptor and progesterone receptor expression, and a positive linear relationship between Oncotype DX recurrence score and Ki67 labelling index. The authors state that “some tumour features such as tumour grade, type, PR status and Ki67 index can be used as surrogate markers in certain scenarios.” The authors concluded that “Oncotype DX RS is correlated strongly with the conventional clinicopathological parameters” (Lashen et al., 2023).

EndoPredict

EndoPredict® (EP) (Myriad Genetic, Inc.) is a breast cancer prognostic test that assesses the expression of eight target genes as compared to three housekeeping (normalization) genes and one additional control gene to detect contamination by residual DNA. The results of this testing are combined to produce a clinical score to determine whether the breast cancer is at high- or low-risk of possible recurrence within ten years (Myriad, 2024a; Warf et al., 2017).

According to the Myriad EndoPredict® Technical Specifications (Effective Date: December 21, 2021), if the test is used on resected tissue, the 12-gene molecular score is then “combined with tumor size and lymph node status to generate an EPclin Risk Score associated recurrence risks and estimated absolute benefit of chemotherapy” whereas “the molecular score and its associated 10-year risk of distant recurrence...are provided” if the sample is a biopsy specimen (Myriad, 2021). The target genes in the EndoPredict® test include the following (Filipits et al., 2019; Warf et al., 2017):

- *BIRC5*
- *DHCR7*
- *UBE2C*
- *AZGP1*
- *IL6ST*
- *MGP*
- *RBBP8*
- *STC2*

Filipits et al. (2011) validated EP’s 11 gene version (only missing the one gene to control for DNA contamination, HBB). The investigators combined these gene expression results with nodal status and tumor size into a risk score (“EPclin”). Two cohorts of 378 and 1324 samples were used in this study, and both cohorts demonstrated that the risk score produced was an independent predictor of distant recurrence. The investigators calculated that EPclin had superior prognostic power compared to solely clinicopathologic

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

factors. EPclin was also found to result in a 4% rate of recurrence for both low-risk cohorts in each sample, a 28% recurrence rate in the “high risk” portion of the 378-item sample, and a 22% recurrence rate in the “high risk” portion of the 1324-item sample. The authors concluded that “the multigene EP risk score provided additional prognostic information to the risk of distant recurrence of breast cancer patients, independent from clinicopathologic parameters. The EPclin score outperformed all conventional clinicopathologic risk factors (Filipits et al., 2011; Myriad, 2024b).”

Two studies by Sestak et al. (2018) have also shown the clinical validity and utility of EndoPredict® testing in women with node-positive breast cancer (Sestak et al., 2018; Sestak et al., 2019). One study consisted of both node-positive and node-negative women (n=3746) to compare the performance of EPclin for predicting distant recurrence in women who had either received endocrine therapy (ET) alone or ET with chemotherapy (ET+C). “In this comparative non-randomized analysis, the rate of increase in DR with EPclin score was significantly reduced in women who received ET + C versus ET alone. Our indirect comparisons suggest that a high EPclin score can predict chemotherapy benefit in women with ER-positive, HER2-negative disease (Sestak et al., 2019).” In the other study, the researchers compared the performance of six different prognostic signatures for ER-positive breast cancer in two different patient groups—node-negative and node-positive. The six tests include EndoPredict®, Breast Cancer Index (BCI), Clinical Treatment Score (CTS), IHC4, ROR, and RS. Within the node-positive cohort (n=277), the authors report the highest univariate hazard ratio (HR) for EPclin (1.69) compared to 1.39 for RS (Sestak et al., 2018).

Another study (n=1702) compared the use of EndoPredict® in node-positive and node-negative women treated with endocrine therapy only. This study assessed both the 10- and 15-year distant recurrence-free rate (DRFR). Similar to node-negative individuals, the 10-year DRFR for patients with one to three positive nodes improved significantly higher than for the full cohort (95.6% versus 80.9%, respectively). “The molecular and EPclin scores were significant predictors of DRFR after adjusting for clinical variables, regardless of nodal status” (Filipits et al., 2019).

Evidence of EndoPredict’s ability to produce a change in therapeutic management abound. For example, Villarreal-Garza et al. (2020) enrolled 99 premenopausal women with a median age of 43 and with hormone receptor-positive, HER2-negative, T1-T2, and N0-N1 breast cancer, and the cases were presented to a multidisciplinary tumor board. The researchers reported that a “change in chemotherapy or endocrine therapy regimen was suggested in 19% and 20% of cases” when EPclin results were made available. Moreover, it was reported that a significant difference could be “found in the median EPclin score between patients with a low- vs. high-intensity chemotherapy and endocrine therapy regimen recommendation (p = 0.049 and p = 0.0001, respectively)”, which may have contributed to high final treatment adherence (93%) in premenopausal patients (Villarreal-Garza et al., 2020).

Dubsky et al. (2020) used hormone receptor (HR)-positive, HER2-negative samples from patients in the ABCSG-34 randomized phase II trial to generate a 12-gene molecular score with the goal of assessing EndoPredict’s ability to predict response to neoadjuvant chemotherapy (NaCT) or neoadjuvant endocrine therapy (NET). The patients in the study were assigned to receive either NaCT or NET based on menopausal status, HR expression, grade and Ki67, and their responses to their assigned therapies were measured by using residual cancer burden (RCB). It was reported that the 12-gene molecular score significantly predicted treatment response for NaCT and NET, boasting areas under the curve (AUC) of 0.736 and 0.726 respectively. Based on these results, it was concluded that “Tumors with low MS were unlikely to benefit from NaCT, whereas a high MS predicted resistance to NET”, further motivating the use of EndoPredict to provide personalized treatment to patients (Dubsky et al., 2020).

Breast Cancer Index

The Breast Cancer Index (BCI) is a combination of two profiles, the HOXB13-to-IL17BR expression ratio (H:I ratio) and the Molecular Grade Index (MGI). This combination is intended to report “whether or not an additional five years of anti-estrogen therapy is likely to help reduce the risk of the cancer returning” and “the

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

individual risk of recurrence after 5 years based on the original tumor biology.” The five genes the MGI examines are *BUB1B*, *CENPA*, *NEK2*, *RACGAP1*, and *RRM2* (Biotheranostics, 2023). Using genome-wide microarray analysis, three differentially expressed genes that were associated with an increased risk of progression among ER-positive patients treated with tamoxifen were: the antiapoptotic homeobox B13 (*HOXB13*, overexpressed in tamoxifen recurrent cases) and both interleukin 17B receptor (*IL17BR*) and *EST AI240933* (both overexpressed in tamoxifen nonrecurrent cases) (Foukakis & Bergh, 2022).

This MGI ratio was validated by separate 410-sample and 323-sample cohorts, and its interaction with the H:I ratio was evaluated. The authors found that “high MGI was associated with significantly worse outcome only in combination with high *HOXB13:IL17BR*, and likewise, high *HOXB13:IL17BR* was significantly associated with poor outcome only in combination with high MGI.” The investigators concluded that “the combination of MGI and *HOXB13:IL17BR* outperforms either alone and identifies a subgroup (~30%) of early stage estrogen receptor-positive breast cancer patients with very poor outcome despite endocrine therapy (Ma et al., 2008).

The BCI has been recently demonstrated to be discerning in other respects. The IDEAL trial attempted to answer the pressing question of the optimal duration of extended endocrine therapy (EET), after completing five years of initial aromatase inhibitor (AI)-based adjuvant therapy (Liefers et al., 2020). The IDEAL trial assessed the ability of BCI (H/I) to predict endocrine benefit of 2.5 vs. 5 years of extended letrozole using available tumor specimen samples from 908 HR+ patients (73% lymph node-positive, disease free at 2.5 years), with 88% and 68% of which were receiving prior treatment with an aromatase inhibitor (AI) or chemotherapy, respectively. It was found that BCI by H/I status (High vs. Low) was “significantly predictive of response from extended letrozole in the overall (N = 908) and pN+ [lymph node-positive] (N = 664) cohorts”, leading the researchers to exalt the BCI as an important genomic tool for future use (Liefers et al., 2020).

Predictor Analysis of Microarray 50

The Predictor Analysis of Microarray 50 (PAM50, by Prosigna) is a 50-gene test that characterizes an individual tumor by intrinsic subtype. It was designed to determine the intrinsic subtype of a cancer using only 50 prespecified genes. The four subtypes are “luminal A, luminal B, HER2-enriched, and basal-like” (Parker et al., 2009). Results from the PAM50 are used to generate the risk of recurrence (ROR) score, which can stratify patients with ER-positive disease into high, medium, and low subsets. The test can be performed on formalin-fixed, paraffin-embedded tissue with a high degree of analytical validity (Nielsen et al., 2010; Foukakis & Bergh, 2022).

This test was validated by Parker et al. (2009). The investigators developed this 50-gene set from 189 prototype samples and evaluated 761 patients for prognosis. The four discrete subtypes were found to be prognostically significant and predicted neoadjuvant chemotherapy efficacy with a negative predictive value for pathologic complete response (to ataxane and anthracycline regimen) of 97%. The authors concluded “diagnosis by intrinsic subtype adds significant prognostic and predictive information to standard parameters for patients with breast cancer (Parker et al., 2009).”

Recently, the intrinsic molecular subtype generated by the Prosigna assay has been demonstrated to be useful in guiding the inclusion and exclusion of an anthracycline to CMF-based chemotherapy. The DBCG89D trial randomized 980 high-risk early breast cancer patients to adjuvant CMF (cyclophosphamide, methotrexate and fluorouracil) or CEF (cyclophosphamide, epirubicin and fluorouracil), ultimately using the data from 686 tumor samples. Continuous ROR score was associated with distant recurrence for CMF and CEF (hazard ratios of 1.20 and 1.04, respectively), and distant recurrence was reported to be significantly longer in those patients with HER2-enriched tumors treated with CEF than with CMF. The results suggested that the benefit of CEF as compared to CMF correlate with an increasing ROR score, and so “patients with Her2-enriched breast cancer derived substantial benefit from anthracycline chemotherapy whereas anthracyclines are not an essential component of chemotherapy for patients with luminal subtypes”, and, similarly, “A benefit from substituting methotrexate with epirubicin is observed among patients with Her2-enriched or Basal-like

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

subtypes whereas there is a lack of such benefit among patients with a Luminal A or Luminal B subtypes” (Jensen et al., 2020). However, the authors admit that the results of the study may potentially be skewed by the retrospective evaluation’s use of only a small subset of patients’ data and the lack of optimal instrumentation and testing, since one-third of the patients were ER-positive but endocrine therapies were not employed (Jensen et al., 2020).

MammaPrint

MammaPrint is a 70-gene test that assesses the risk of recurrence within the first 5-10 years of diagnosis. The test reports risk in one of two categories, “low” and “high”. MammaPrint’s validation places “low” risk at a 1.3% chance (95% confidence interval: 0-3.1%) that cancer will recur in 5 years whereas those classified as “high” risk have a 11.7% chance for the cancer to recur in five years (95% confidence interval: 6.6%-16.8%) (Agendia,2014,2024b). Agendia offers other breast cancer assessments, such as Blueprint. Blueprint is an 80-gene molecular subtyping assay, which “analyzes the activity” of its genes. It is proposed to identify a tumor’s molecular “subtype”: luminal A/B, basal, or HER2. Each subtype has varying molecular characteristics (ER-positive or negative, HER2-positive or negative, et al), which is proposed to help clinicians provide targeted treatment for a patient (Agendia, 2024a).

MammaPrint was validated by Cardoso et al. (2016). The authors determined the risk recurrence of 6693 patients. Of these 6693 patients, 1550 of them were found to have high clinical risk and low genomic risk, and the rate of survival without distant metastasis in this cohort was 94.7% among those not receiving chemotherapy. The difference in survival rate between these patients and those receiving chemotherapy was 1.5%. The authors estimated that “given these findings, approximately 46% of women with breast cancer who are at high clinical risk might not require chemotherapy” (Cardoso et al., 2016).

However, it may be possible that new prognostic assays are beginning to make their foray. Prat et al. (2020) derived a prognostic assay that integrates multiple data types for predicting survival outcome in patients with newly diagnosed HER2-positive breast cancer to aid treatment decisions for those with early-stage HER2-positive breast cancer, where escalation or de-escalation of systemic therapy is a point of contention. Using clinical-pathological data on stromal tumor-infiltrating lymphocytes, PAM50 subtypes, and expression of 55 genes obtained from patients who participated in the Short-HER phase 3 trial, Prat et al. (2020) then evaluated their model based on a combined dataset of 267 patients with early-stage HER2-positive breast cancer treated with different neoadjuvant and adjuvant anti-HER2-based combinations and from four other studies (PAMELA, CHER-LOB, Hospital Clinic, and Padova) with disease-free survival outcome data. The final model, named HER2DX, was comprised of data from 435 (35%) of 1254 patients for tumor size (T1 vs rest), nodal status (N0 vs rest), number of tumor-infiltrating lymphocytes (continuous variable), subtype (HER2-enriched and basal-like vs rest), and 13 genes. The authors exalt the analytical power of HER2DX by reporting that it was “significantly associated with disease-free survival as a continuous variable” and reported that the 5-year disease-free survival in the HER2DX low-risk group was 93.5% (89.0-98.3%) whereas the high-risk group reported 81.1% (71.5-92.1). The researchers assert that HER2DX “identifies patients with early-stage, HER2-positive breast cancer who might be candidates for escalated or de-escalated systemic treatment” and that “Future clinical validation of HER2DX seems warranted to establish its use in different scenarios, especially in the neoadjuvant setting” (Prat et al., 2020).

DCISionRT®

The DCISionRT test out of Prelude Corporation aims to provide patients with three results: 1) their overall score (continuous risk score and low vs elevated category, 2) their rate of recurrence over 10 years, and 3) their benefit from radiation. The intended demographic is females aged 26 and older who have been diagnosed with ductal carcinoma in situ (DCIS) of the breast, and who have been treated with breast conserving surgery or a core biopsy (PreludeDx, 2024).

Recognizing that patients diagnosed with DCIS are at risk of recurrence (30%) within 10 years following breast conserving surgery and that election of RT is not always beneficial, the SweDCIS randomized clinical

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

trials also investigated the validity of the DCISionRT biosignature, which combines an evaluation of protein expression (PR, HER2, Ki67, FOXA1, p16/INK4A, SIAH2, COX2) with clinicopathologic factors (age, tumor size, margin status, palpability) and mapped it along a continuous Decision Score (DS) on a scale of 1 to 10 with corresponding 10-year risks after breast conserving surgery with and without radiation therapy (Wärnberg et al., 2021). The authors found that “using the pre-specified DS threshold of 3.0 to define DS Low and Elevated Risk groups, approximately 50% of women were classified into the Elevated Risk group”, which is significant as many women who would have been erroneously sorted into one risk group based on classical clinicopathology were found to be better reclassified into opposite risk groups based on their DS. Finally, in the DS Elevated Risk group, the addition of radiation therapy was found to reduce absolute 10-year rates for TotBE by 15.9%, and for InvBE by 9.4%, while the DS Low Risk Group boasted 10-year DCIS rates of 0.7% and 5.2%, and InvBE rates of 6.5% and 7.7%, with and without RT, respectively, indicating to the authors that “Radiotherapy benefit was statistically significant in patients with elevated DS but not in patients with low DS by DCISionRT”, though it is also admitted that this evaluation may not reflect modern practice and modern risk profiles because the women participating in the trials were randomly assigned between 1987 and 2000 (Wärnberg et al., 2021).

Bremer et al. (2018) reported on the development and the cross-validation of the DCISionRT biosignature using archived tissue samples from Uppsala University Hospital and Västmanland County Hospital, Sweden (UUH), from 1986 and 2004 and samples from between 1999 and 2008 at the University of Massachusetts, Worcester (UMass), in collaboration with PreludeDx. The study population comprised 721 female patients diagnosed with a primary DCIS and treated with BCS identified from 2 study sites, with mean and median follow-ups of 10 years and 9 years, respectively. Here, the authors found the Decision Score reclassified greater than 50% of the low- and intermediate-grade patients as elevated risk, and 33% of patients that were grade III or had tumor size >2.5 cm were reclassified as low risk. Moreover, it was found that in the low clinicopathological risk group—defined to have tumor size less than 25 mm, low or intermediate grade, and nonpalpable and clear margins—DS reclassified 42% of these patients into the Elevated Risk Group (DS > 3.0). When a linear panel using weighted clinicopathologic and molecular factors to assess recurrence risk was constructed for comparison with the proprietary biosignature, it could not identify a clinically meaningful low-risk group. The researchers reported that “These reclassified patients had substantial 10-year risks, 23% (95% CI: 7%–36%) IBC and 31% (95% CI: 14%–45%) IBE, when not treated with RT” and that while patients in the DS Low Group had similar outcomes regardless of whether they received RT, patients treated with RT and classified into the Elevated Risk Group received a 70% or greater risk reduction than those without RT (Bremer et al., 2018). As such, Bremer et al. (2018) claims that these “findings reflect the effectiveness of the biological signature to identify patients with favorable tumor biology and separate them from the Elevated Risk Group of patients that have the highest likelihood of recurrence.”

These results corroborate other investigations into the utility of DCISionRT in guiding treatment management. The prospective, multi-institutional PREDICT study found that DCISionRT testing can lead to great changes in radiation therapy recommendations, such that of the 539 women participating in the study, 69% were initially slated RT pre-test ($n = 374$) by treating clinicians based on traditional clinicopathology and 46% were recommended to not receive RT post-test ($n = 165$). But of those initially recommended to not receive RT ($n = 165$), 35% were then recommended to receive RT post-test ($n = 58$). As such, the authors reported a significant overall change in the RT recommendation for 42% of women ($n = 539$, $p < 0.001$) and a net reduction in the RT recommendation by 20% (Shah et al., 2021). Furthermore, after DCISionRT testing, elevated versus low DCISionRT score (DS > 3 vs. DS ≤ 3) was found to be the strongest factor for an RT recommendation (odds ratio of 43.1) compared against all other factors (age, grade, tumor size, margin status, patient preference). However, the authors acknowledge that there exist limitations to the study, namely that long-term clinical outcomes and satisfaction ratings from patients and physicians are unavailable for analysis and that data for RT recommendations are limited to post-surgery/pre-testing and post-surgery/post-testing time points (Shah et al., 2021). Thus, while the results seem promising, the real predictive power of the DCISionRT test is still uncertain. Additional information will be critical to evaluating the test’s value and valence—whether positive or negative—in ultimately determining the benefit of adjuvant RT following BCS.

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

Dabbs et al. (2023) studied the analytical validity, performance assessment, and clinical performance validation and clinical utility for the DCISionRT test. The authors performed an analytical validation assessment on multiple DCIS molecular assays; the analytical validation test was conducted based on Clinical and Laboratory Standards Institute guidelines. “The analytic validation showed that the molecular assays that are part of DCISionRT test have high sensitivity, specificity, and accuracy/reproducibility ($\geq 95\%$).” The authors concluded that the DCISionRT has high analytical validity (Dabbs et al., 2023).

BBDRisk Dx®

The BBDRisk Dx® test is “the first genomic risk test designed specifically for women diagnosed with breast masses that have one or more of the following: Atypical Ductal Hyperplasias (ADH), Atypical Lobular Hyperplasia (ALH), Usual Ductal Hyperplasias (UDH), Papilloma and Sclerosing Adenosis” (BBDRiskDx, 2023). The test assays four cancer biomarker oncoproteins—Matrix Metalloproteinase-1 (MMP-1), Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6), Hyaluronoglucosaminidase 1 (HYAL1), Highly Expressed in Cancer Protein 1 (HEC1)—requiring a sample of formalin fixed paraffin embedded (FFPE) tissue for the immunohistochemistry. The four-marker profile is then rendered to produce a Cancer Risk Score between the range of 0 and 10, classifying the patient into the ‘Low Risk’ Group (Risk Score ≤ 0.5), the ‘Intermediate Risk’ group (>0.5 but ≤ 5.4), and the ‘High Risk’ group (>5.4). These scores help provide the patient with information about their chances of developing future breast cancer over 5 to 10 years—as compared with women with similar profiles—and guide physician discretion in proposing prophylactic endocrine treatments and or surgery (Silbiotech, 2021).

Poola et al. (2019) explored the effectiveness of the four-marker signature of MMP-1, CEACAM6, HYAL1, and HEC1 in identifying the benefit that high-risk patients presenting atypical and nonatypical hyperplasias would derive from preventive therapies. A total of 440 tissues were included in the study and categorized into two groups: a cancer group of 162 specimens that developed DCIS after a minimum of one year and a maximum of 13 years, and a cancer-free group of 278 specimens from subjects who did not have prior breast cancer and did not develop for a minimum of five years and a maximum of 19 years. A ‘cancer risk score’ (composite value between 0 and 10) was obtained by combining the multiple marker levels through using piecewise linear regression (Poola et al., 2019). From constructing box plots and density plots of the scores generated from the 440 samples, the authors found that in the risk scores of the cancer-free group peaked around 0.5, while the scores peaked around 9.0 for the cancer group, suggesting that the “risk signature segregates the cancer group from the cancer-free group of tissues”. Moreover, analysis of the risk scores between atypical and nonatypical tissues for any differences using *t* test, yielded significantly higher values in the cancer group of atypical tissues ($P = 0.02$) than the nonatypical tissues but the authors did not find any significant differences in the cancer-free groups. Plots produced from Kaplan-Meier survival analysis demonstrated that “In the first five years, 53% of subjects in the high-risk group, 12% in the intermediate-risk group, and 1% in the low-risk group developed cancer”, and 73% of atypical subjects in high-risk group developed cancer in the first five years, while in the nonatypical group the cancer rates were only 34%. Meanwhile, mapping cancer risk scores to percent cancer rates in five years, 10 years, 15 years, and beyond 15 years produced a direct and positive correlation (Poola et al., 2019).

Clinical Utility and Validity

Blok et al. (2018) performed a meta-analysis of the MammaPrint, OncotypeDX, PAM50/Prosigna and Endopredict assays. The authors investigated the evidence available on both the clinical utility and economic value of these assays. Most of the observed studies concluded that genomic profiling contributed to less chemotherapy use. However, the authors caution that “absolute numbers should be interpreted carefully, since some tests are less frequently studied than others” especially as “the clinical consensus on adjuvant chemotherapy is that we are most likely over-treating our patients, since we are not capable of identifying patients that will or will not benefit from chemotherapy using the current clinicopathological parameters”. The authors note that Petkov et al. retrospectively matched OncoType DX use with SEER registry data for over 40000 patients and found that “patients with node negative, HR+, HER2-breast cancer which underwent testing ($n = 40,134$, 22.7% chemotherapy) had no lower chemotherapy use

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

compared to patients that were not tested (n = 144,056, 22.2% chemotherapy)". The authors noted that 90% of the 44 economic analyses concluded that genomic testing was cost-effective; however, various biases are mentioned (publication bias, publications using overlapping samples, and more) (Blok et al., 2018).

Gustavsen et al. (2014) performed an economic analysis of the Breast Cancer Index and found that "Costs associated with adjuvant chemotherapy, toxicity, followup, endocrine therapy, and recurrence were modeled over 10 years. The models examined cost utility compared with standard practice when used at diagnosis and in patients disease-free at five years post diagnosis." The authors calculated BCI to save approximately \$3803 per patient for the newly diagnosed population and \$1803 per patient in the five years post diagnosis population. These savings were projected to come from "adjuvant chemotherapy use, extended endocrine therapy use, and endocrine therapy compliance" (Gustavsen et al., 2014).

Camp et al. (2019) investigated a new reinterpretable technique of the PAM50 assay. The authors reorganized the gene expression data provided by the assay into five "quantitative, orthogonal, multi-gene breast tumor traits" and stated that these "dimensions" better represented breast cancer pedigrees. They re-assessed the data of the GEICAM/9906 clinical trial with these dimensions. After reorganization, the authors concluded that dimensions "PC1 and PC5" were associated with disease-free survival, and low "PC3 and PC4" indicated response to paclitaxel. However, high PC3 or PC4 did not show survival advantage (Camp et al., 2019).

Wuerstlein et al. (2019) evaluated the clinical utility of MammaPrint and its intended adjunct test, Blueprint. Physicians were asked to provide initial therapy recommendations (based on clinicopathological factors), then were provided results of MammaPrint/Blueprint risk stratifiers. Then the same physicians provided new treatment recommendations, and the subsequent treatment was recorded. The authors identified a switch in treatment in 29.1% of cases. Physician adherence to MammaPrint risk assessment was over 90% in both groups of risk (low and high). Even when physicians and risk stratifiers disagreed, the physicians tended to recommend treatments based on the risk stratifier. Overall, the authors concluded that "MammaPrint and Blueprint test results strongly impacted physicians' therapy decisions in luminal EBC with up to three involved lymph nodes" (Wuerstlein et al., 2019).

Toole et al. (2014) evaluated the similarities and differences in genetic profiles between primary breast cancers in patients with multiple primaries. The authors also evaluated whether obtaining genetic profiling scores (OncoType DX) on each primary affected chemotherapy decisions. In total, 22 patients had multiple tumor samples sent for analysis, and the authors found that six patients had their chemotherapy recommendations changed based on differing OncoType scores (between their samples). The authors also noted that scores tended to differ more between tumors appearing simultaneously on different breasts compared to multiple tumors on the same breast (Toole, Kidwell, & Van Poznak, 2014).

Martin et al. (2016) compared the use of EndoPredict® (EPclin) and PAM50 risk of recurrence (ROR) scores in node-positive breast cancer to predict distant metastasis-free survival (MFS). ROR scores can be based using subtype (ROR-S); subtype and proliferation (ROR-P); subtype and tumor size (ROR-T); and subtype, proliferation, and tumor size combined (ROR-PT). They found that "Predictors including clinical information showed superior prognostic performance compared to molecular scores alone (10-year MFS, low-risk group: ROR-T 88 %; ROR-PT 92 %; EPclin 100 %). The EPclin-based risk stratification achieved a significantly improved prediction of MFS compared to ROR-T, but not ROR-PT (Martin et al., 2016)."

Ding et al. (2019) used the 21-gene recurrence score for patients with pure mucinous breast cancer (PMBC). This multi-year study of 8048 female PMBC patients categorized the patients based on RS risk groups of low, intermediate, and high RS risk groups. They found the distribution to be 64.9%, 31.9%, and 3.2%, respectively. For PMBC patients, the authors note that PMBC patients do show significantly different 5-year survival rates based on ER status. They do conclude that RS can be used with PMBC patients...age, progesterone receptor status, and grade could independently predict RS" (Ding et al., 2019). These data support the findings of a considerably smaller comparative study (n=35 PMBC patients and n=70 IDC patients) that show on average PMBC patients score lower than IDC patients (average RS 21.26 and 24.40, respectively); however, they authors do conclude that "patients with high RS in the PMBC group might be

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

recommended to receive adjuvant chemotherapy” since 8.57% of PMBC patients have RS scores within the highest risk stratification (W. Wang et al., 2018). Both studies contradict an earlier, smaller study (n=10 TC patients and n=33 MC patients) that reported no patients within the high-risk RS category (Turashvili et al., 2017).

Kizy et al. (2018) conducted a large retrospective study of various subtypes of T1-T2N0 estrogen receptor-positive breast cancer (n=83665) was published in 2018. Both mucinous and tubular histologies were included in the study. The authors note considerable differences in RS scores between the various histologies; for example, they found that 1.0% and 28.5% of tubular adenocarcinoma patients had RS scores in the high and intermediate ranges, respectively, whereas mucinous adenocarcinoma patients fared worse with 3.4% and 28.8%, respectively. It should be noted, however, that only 2.1% of the patients included in the study had been diagnosed with mucinous adenocarcinoma and 0.6% with tubular adenocarcinoma (J. Wang et al., 2018). Similarly, a study by Kizy et al also reports that 4% of tubular carcinoma patients were classified as high risk based on the Trial Assigning Individualized Options for Treatment RS criteria (Kizy et al., 2018).

Harnan et al. (2019) released an in-depth systemic review of the effectiveness and cost-effectiveness of Oncotype DX®, MammaPrint®, Prosigna®, EndoPredict®, and immunohistochemistry 4 (IHC4) was released in 2019 (Harnan et al., 2019). For this review, the authors included a total of 153 studies, including the MINDACT RCT for MammaPrint. The authors note that a limitation of this systemic review, and of the current field in general, is that only one RCT has been completed to date. Their results include the following:

- “There is limited and varying evidence that oncotype DX and MammaPrint can predict benefit from chemotherapy.”
- “The health economic analysis suggests that the incremental cost-effectiveness ratios for the tests versus current practice are broadly favorable for the following scenarios: (1) oncotype DX, for the LN0 subgroup with a Nottingham Prognostic Index (NPI) of > 3.4 and the one to three positive lymph nodes (LN1–3) subgroup (if a predictive benefit is assumed); (2) IHC4 plus clinical factors (IHC4+C), for all patient subgroups; (3) Prosigna, for the LN0 subgroup with a NPI of > 3.4 and the LN1–3 subgroup; (4) *EndoPredict Clinical, for the LN1–3 subgroup only* [emphasis added]; and (5) MammaPrint, for no subgroups (Harnan et al., 2019).”

Qi et al. (2021) examined the efficacy of the 21-gene assay (Oncotype DX) in core needle biopsies (CNB) as compared to breast cancer resection specimens (the gold standard for obtaining IHC or other molecular information, as they exhibit the most abundant tumor characteristics). The 21-gene assay can be applied to a CNB and CNBs do have the advantage of having a more standardized fixation protocol as compared to resection specimens, which have many different protocols available and often have a greater time between loss of blood supply and the initiation of fixation due to the complexity of surgery. While CNBs are more reliable in determining hormone receptor status due to decreased loss of antigens from the fixation process that resection specimens undergo, CNBs cannot account for crush artefacts which can lead to inaccurate results because of tumor heterogeneity. CNBs are also less accurate than resection specimens in determining the histological characteristics of a tumor, such as tumor invasiveness and tumor grade. It’s also important to note that intratumoral heterogeneity can lead to an underestimation of tumor genomic characteristics because of varying gene expression signations found within different regions of the same tumor.

Qi et al. (2021) utilized a paired CNB and resection specimen approach to assess the concordance of the Oncotype DX results between the CNB and resection samples. They found that determination of 21-gene assay results from CNBs are reliable, providing results which closely parallel those obtained from resection specimens. However, there is no clear data indicating that tumor grade can be determined using a CNB sample (Qi et al., 2021).

Sennerstam et al., (2017) conducted a retrospective study looking at the long-term outcomes of patients with breast cancer diagnosed with fine-needle aspiration biopsy (FNAB) vs CNB in the 1970s and the 1990s

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

(diagnosis using FNAB from 1971-1976 (n=354); diagnosed using CNB from 1991-1995 (n=1,729)) shows a potentially alarming trend. The authors treatment, mammography screening, tumor size, DNA ploidy, and patient age matched samples from the two decades to get two strictly matched samples representing FNAB (n=181) and CNB (n=203), which were selected for a 15-year follow-up study. When comparing the rates of distant metastasis in the strictly matched patient groups, they found that 5-15 years after diagnosis of the primary tumor, patients diagnosed via CNB had significantly higher rates of metastases as compared to those diagnosed via FNAB (Sennerstam et al., 2017).

Guidelines and Recommendations

American Society of Clinical Oncology (ASCO)

In 2016, ASCO provided recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. ASCO recommends that “in addition to estrogen and progesterone receptors and human epidermal growth factor receptors 2, the panel found sufficient evidence of clinical utility for the biomarker assays *Oncotype DX*, *EndoPredict*, *PAM50*, *Breast Cancer Index*, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific subgroups of breast cancer” (Harris, 2016).

ASCO made the following recommendations:

- If a patient has ER/PgR-positive, HER2-negative (node-negative) breast cancer, the clinician may use the 21-gene recurrence score to guide decisions on adjuvant systemic chemotherapy. Type: evidence based. Evidence quality: high. Strength of recommendation: strong.
- If a patient has ER/PgR-positive, HER2-negative (node-positive) breast cancer, the clinician should not use the 21-gene RS to guide decisions on adjuvant systemic chemotherapy. Type: evidence based. Evidence quality: intermediate. Strength of recommendation: moderate.
- If a patient has HER2-positive breast cancer or TN breast cancer, the clinician should not use the 21-gene RS to guide decisions on adjuvant systemic therapy. Type: informal consensus. Evidence quality: insufficient. Strength of recommendation: strong.
- If a patient has ER/PgR-positive, HER2-negative (node-positive) breast cancer, the clinician should not use the Breast Cancer Index, the PAM50-ROR, the 12-gene risk score, or the 21-gene RS, (*EndoPredict*), to guide decisions on adjuvant systemic therapy.
- If a patient has ER/PgR-positive, HER2-negative (node-negative) breast cancer, the clinician may use urokinase plasminogen activator (uPA), plasminogen activator inhibitor type 1 (PAI-1), the Breast Cancer Index, the PAM50 risk of recurrence (ROR) score, the 12-gene risk score (*EndoPredict*), and the 21-gene recurrence score (*Oncotype DX*) to guide decisions on adjuvant systemic therapy. If the patient has had 5 years of endocrine therapy without evidence of recurrence, the clinician should not use multiparameter gene expression or protein assays (*Oncotype DX*, *EndoPredict*, *PAM50*, *Breast Cancer Index*, or *IHC4*) to guide decisions on extended endocrine therapy.
- If a patient has HER2-positive breast cancer or TN breast cancer, the clinician should not use uPA, *IHC4*, the 12-gene risk score (*EndoPredict*), PAI-1, the 21-gene RS (*Oncotype DX*), the five-protein assay (*Mammostrat*), the Breast Cancer Index or *TILs* to guide decisions on adjuvant systemic therapy. The clinician should not use circulating tumor cells (CTCs) to guide decisions on adjuvant systemic therapy.
- If a patient has HER2-positive breast cancer, the clinician should not use the PAM50-ROR to guide decisions on adjuvant systemic therapy.
- If a patient has TN breast cancer, the clinician should not use the PAM50-ROR to guide decisions on adjuvant systemic therapy (Harris et al., 2016).

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

In 2017 the ASCO (Krop et al., 2017), based on a review of the MINDACT study publication, revised their guidelines on Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer to state the following:

Recommendation 1.1.1 (update of Recommendation 1.7).

If a patient has **ER/PgR–positive, HER2–negative, node–negative**, breast cancer, the MammaPrint assay may be used in those with **high clinical risk** per MINDACT categorization to inform decisions on withholding adjuvant systemic chemotherapy due to its ability to identify a good prognosis population with potentially limited chemotherapy benefit (Type: evidence based; Evidence quality: high; Strength of recommendation: strong).

Recommendation 1.1.2 (update of Recommendation 1.7).

If a patient has **ER/PgR–positive, HER2–negative, node–negative**, breast cancer, the MammaPrint assay **should not** be used in those with **low clinical risk** per MINDACT categorization to inform decisions on withholding adjuvant systemic chemotherapy as women in the low clinical risk category had excellent outcomes and did not appear to benefit from chemotherapy even with a genomic high-risk cancer (Type: evidence based; Evidence quality: high; Strength of recommendation: strong).”

Recommendation 1.2.2: (update of 2016 recommendation 1.7): If a patient has **ER/PgR–positive, HER2–negative, node–positive**, breast cancer, the MammaPrint assay should not be used in patients with one to three positive nodes and at low clinical risk per MINDACT categorization to inform decisions on withholding adjuvant systemic chemotherapy. There are insufficient data on the clinical utility of MammaPrint in this specific patient population (Type: informal consensus; Evidence quality: low; Strength of recommendation: moderate).

Recommendation 1.3: (update of 2016 recommendation 1.8): If a patient has **HER2–positive** breast cancer, the clinician should not use the MammaPrint assay to guide decisions on adjuvant systemic therapy. Additional studies are required to address the role of MammaPrint in patients with this tumor subtype who are also receiving HER2-targeted therapy (Type: informal consensus; Evidence quality: low; Strength of recommendation: moderate).

Recommendation 1.4: (update of 2016 recommendation 1.9): If a patient has **ER/PgR negative and HER2–negative (triple negative)** breast cancer, the clinician should not use the MammaPrint assay to guide decisions on adjuvant systemic chemotherapy (Type: informal consensus; Evidence quality: insufficient; Strength of recommendation: strong) (Krop et al., 2017)”.

ASCO published an update regarding the “Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer”, which was released in response to the results of two phase III trials, MINDACT and TAILORx. The updated guidelines state that the clinical trials found evidence of clinical utility for both node-positive and node-negative patients, but only for patients determined to be at high clinical risk. Therefore, the Panel did not recommend use of MammaPrint for patients determined to be of low clinical risk (Henry et al., 2019).

In a focused update published in 2019, the ASCO addressed the use of Oncotype DX in the following recommendation:

“For patients with hormone receptor–positive, axillary node–negative breast cancer whose tumors have Oncotype DX recurrence scores of less than 26, there is little to no benefit from chemotherapy, especially for patients older than age 50 years. Clinicians may recommend endocrine therapy alone for women older than age 50 years. For patients 50 years of age or younger with recurrence scores of 16 to 25, clinicians may offer chemoendocrine therapy. Patients with recurrence scores greater than 30 should be considered candidates for chemoendocrine therapy. Based on informal consensus, the panel recommends that oncologists may offer chemoendocrine therapy to these patients with recurrence scores of 26 to 30” (Andre et al., 2019).

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

In 2022, the ASCO released a guideline update on biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer. The ASCO recommends that:

- **“Recommendation 1.1.** If a patient has node-negative breast cancer, the clinician may use the Oncotype DX test to guide decisions for adjuvant endocrine and chemotherapy (Type: evidence-based; Evidence quality: high; Strength of recommendation: strong).
- **Recommendation 1.2.** In the group of patients in Recommendation 1.1 with Oncotype DX recurrence score greater or equal to 26, the clinician should offer chemoendocrine therapy (Type: evidence-based; Evidence quality: high; Strength of recommendation: strong).
- **Recommendation 1.3.** In the group of patients in Recommendation 1.1 who are 50 years of age or younger with Oncotype DX recurrence score 16 to 25, the clinician may offer chemoendocrine therapy (Type: evidence-based; Evidence quality: intermediate; Strength of recommendation: moderate).
- **Recommendation 1.4.** If a patient is postmenopausal and has node-positive breast cancer with 1-3 positive nodes, the clinician may use the Oncotype DX test to guide decisions for adjuvant endocrine and chemotherapy (Type: evidence-based; Evidence quality: high; Strength of recommendation: strong).
- **Recommendation 1.5.** In the group of patients in Recommendation 1.4, the clinician should offer chemoendocrine therapy for those whose Oncotype DX recurrence score is ≥ 26 (Type: evidence-based; Evidence quality: high; Strength of recommendation: strong).
- **Recommendation 1.6.** If a patient is premenopausal and has node-positive breast cancer with 1-3 positive nodes, Oncotype DX test should not be offered to guide decisions for adjuvant systemic chemotherapy (Type: evidence-based; Evidence quality: high; Strength of recommendation: moderate).
- **Recommendation 1.7.** If a patient has node-positive breast cancer with ≥ 4 positive nodes, the evidence on the clinical utility of routine Oncotype DX to guide decisions for adjuvant endocrine and chemotherapy is insufficient to recommend its use (Type: informal consensus; Evidence quality: insufficient; Strength of recommendation: moderate)” (Andre et al., 2022).

American Cancer Society (ACS)

In 2017, the American Cancer Society (ACS) released a revision to the American Joint Cancer Committee’s Eighth Edition Cancer Staging Manual. The revision suggests that:

“For patients with hormone receptor-positive, HER2-negative, and lymph node-negative tumors, a21-gene (Oncotype Dx) recurrence score less than 11, regardless of T size, places the tumor into the same prognostic category as T1a-T1b N0 M0, and the tumor is staged using the AJCC prognostic stage group table as stage I.

For patients with hormone receptor-positive, HER2-negative, and lymph node-negative tumors, a Mammaprint low-risk score, regardless of T size, places the tumor into the same prognostic category as T1a-T1b N0 M0.

For patients with hormone receptor-positive, HER2-negative, and lymph node-negative tumors, a12-gene (EndoPredict) low-risk score, regardless of T size, places the tumor into the same prognostic category as T1a-T1b N0 M0.

For patients with hormone receptor-positive, HER2-negative, and lymph node-negative tumors, aPAM50 risk-of-recurrence score in the low range, regardless of T size, places the tumor into the same prognostic category as T1a-T1b N0 M0.

For patients with hormone receptor-positive, HER2-negative, and lymph node-negative tumors, a Breast Cancer Index in the low-risk range, regardless of T size, places the tumor into the same prognostic category as T1a-T1b N0 M0.” (Giuliano et al., 2017)

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

National Comprehensive Cancer Network (NCCN)

The NCCN Clinical Practice Guidelines for Breast Cancer consider five gene expression assays for adjuvant systemic therapy. The five are comprised of the 21-gene Oncotype Dx, the 70-gene MammaPrint, the 50-gene PAM50, the 12-gene EndoPredict, and the Breast Cancer Index (BCI). All five gene expression assays achieved the NCCN Category of Evidence and Consensus grade of 2A (consensus of appropriateness of intervention based on lower-level evidence) or higher, with Oncotype Dx achieving grade 1 (consensus based on higher-level evidence) for node-negative and MammaPrint for achieving grade 1 for node-negative and 1 to 3 positive nodes. It should be noted that NCCN identifies only the as suitable for prediction of chemotherapy benefit: NCCN states that “Other prognostic gene assays can provide prognostic information but the ability to predict chemotherapy benefits is unknown.” BCI is identified as suitable for predicting benefit of extended adjuvant endocrine therapy (NCCN, 2024).

The NCCN Panel “notes that multigene assays provide prognostic and therapy-predictive information that complements TNM and biomarker information”. Below is the table from their recommendations and guidelines based on risk scores and nodal statuses of the multigene assays (NCCN, 2024):

Assay	Recurrence Risk	Treatment Implications
21-gene (Oncotype Dx) (for postmenopausal patients with pN0 and pN1 [1–3 positive nodes])^c	<26	Patients with T1b/c–2, pN0, HR-positive, HER2-negative tumors, with risk scores (RS) between 0–10 have a risk of distant recurrence of <4% and those with RS 11–25 derived no benefit from the addition of chemotherapy to endocrine therapy in the prospective TAILORx study. ¹ Postmenopausal patients with pT1–3, pN1, HR-positive, HER2-negative, with RS <26 derived no benefit from the addition of chemotherapy to endocrine therapy in the prospective RxPONDER study. ²
	≥26	In postmenopausal patients with pT1–3, HR-positive, HER2-negative, and pN0 and pN1 (1–3 positive nodes) tumors and an RS ≥26, the addition of chemotherapy to endocrine therapy is recommended. ¹
21-gene (Oncotype Dx) (for premenopausal patients: pN0)	≤15	Premenopausal patients with T1b/c –2, pN0, HR-positive, HER2-negative tumors with RS <16 derived benefit from the addition of chemotherapy to endocrine therapy in the prospective TAILORx study. ¹
	16–25	In premenopausal patients with RS between 16–25, a small benefit from the addition of chemotherapy could not be ruled out, but it is unclear if the benefit was due to the ovarian suppression effect promoted by chemotherapy in premenopausal patients. ^{1,2} For this group, consider chemotherapy followed by endo therapy or alternatively, ovarian function suppression combined with either tamoxifen or an AI.
	≥26	In premenopausal patients with HR-positive, HER2-negative, and pN0 tumors and an RS ≥26, the addition of chemotherapy to endocrine therapy is recommended. ¹
21-gene (Oncotype Dx) (for premenopausal patients with 1–3 positive nodes)^c	<26	In premenopausal patients with pT1–3 and pN1 (1–3 positive nodes) tumors and an RS <26, the addition of chemotherapy to endocrine therapy was associated with a lower rate of distant recurrence compared with endocrine monotherapy ² but it is unclear if the benefit was due to the ovarian suppression effects promoted by chemotherapy. For this group of patients, consider chemotherapy followed by endocrine therapy or alternatively, ovarian function suppression combined with either tamoxifen or an AI. ²
	≥26	In premenopausal patients with HR-positive, HER2-negative, pT1–3 and pN1 (1–3 positive nodes) tumors and an RS ≥26, the addition of chemotherapy to endocrine therapy is recommended. ²

^a Gene expression assays provide prognostic and therapy-predictive information that complements T,N,M and biomarker information. Use of these assays is not recommended for staging. The 21-gene assay (Oncotype Dx) is preferred by the NCCN Breast Cancer Panel for prognosis and prediction of chemotherapy benefit. Other prognostic gene expression assays can provide prognostic information but the ability to predict chemotherapy benefit is unknown.

^b See [Special Considerations for Breast Cancer in Males \(Sex Assigned at Birth\) \(BINV-J\)](#).

^c In the overall study population of the RxPONDER trial, 10.3% had high-grade disease and 9.2% had 3 involved nodes.

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

Assay	Recurrence Risk	Treatment Implications
70-gene (MammaPrint) (for pN0 and 1-3 positive nodes)	Low	Patients with high clinical risk and low genomic risk were randomly assigned to receive chemotherapy (n = 749) or not (n = 748); this was the intention-to-treat population. The 8-year estimates for distant metastasis-free survival in the intention-to-treat population were 92.0% (95% CI, 89.6–93.8) for chemotherapy versus 89.4% (86.8–91.5) for no chemotherapy (HR, 0.66; 95% CI, 0.48–0.92). An exploratory analysis confined to the subset of patients with HR-positive, HER2-negative disease (1358 [90.7%] of 1497 randomly assigned patients, of whom 676 received chemotherapy and 682 did not) shows different effects of chemotherapy administration on 8-year distant metastasis-free survival according to age: 93.6% (95% CI, 89.3–96.3) with chemotherapy versus 88.6% (83.5–92.3) without chemotherapy in 464 patients aged 50 years or younger (absolute difference 5.0 percentage points [SE, 2.8; 95% CI, –0.5–10.4]) and 90.2% (86.8–92.7) versus 90.0% (86.6–92.6) in 894 females older than 50 years (absolute difference 0.2 percentage points [2.1, –4.0–4.4]). The 8-year distant metastasis-free survival in the exploratory analysis by nodal status in these patients was 91.7% (95% CI, 88.1–94.3) with chemotherapy and 89.2% (85.2–92.2) without chemotherapy in 699 node-negative patients (absolute difference 2.5 percentage points [SE, 2.3; 95% CI, –2.1–7.2]) and 91.2% (87.2–94.0) versus 89.9% (85.8–92.8) for 658 patients with one to three positive nodes (absolute difference 1.3 percentage points [2.4, –3.5–6.1]). ³
	High	
50-gene (Prosigna) (for pN0 and 1-3 positive nodes)	Node negative: Low (0–40), Intermediate (41–60), High (61–100)	For patients with T1 and T2 HR-positive, HER2-negative, pN0 tumors, a risk of recurrence score in the low range, regardless of T size, places the tumor into the same prognostic category as T1a–T1b,N0,M0. ⁴
	Node positive: Low (0–40)	In patients with HR-positive, HER2-negative, pN+ tumors (1–3 positive lymph nodes) with low risk of recurrence score, treated with endocrine therapy alone, the distant recurrence risk was less than 3.5% at 10 years and no distant recurrence was seen at 10 years in the TransATAC study in a similar group. ⁵
	Node positive: High (41–100)	
12-gene (EndoPredict) (pN0 and 1-3 positive nodes)	Low (≤ 3.3)	For patients with T1 and T2 HR-positive, HER2-negative, and pN0 tumors, a 12-gene low-risk score, regardless of T size, places the tumor into the same prognostic category as T1a–T1b,N0,M0. ⁶ In ABCSG 6/8, patients in the low-risk group had risk of distant recurrence of 4% at 10 years and in the TransATAC study, patients with 1–3 positive nodes in the low-risk group had a 5.6% risk of distant recurrence at 10 years. ^{6,7} The assay is prognostic in endocrine and chemo-endocrine treated patients. ⁷
	High (> 3.3)	

^a Gene expression assays provide prognostic and therapy-predictive information that complements T,N,M and biomarker information. Use of these assays is not required for staging. The 21-gene assay (Oncotype Dx) is preferred by the NCCN Breast Cancer Panel for prognosis and prediction of chemotherapy benefit. Other prognostic gene expression assays can provide prognostic information but the ability to predict chemotherapy benefit is unknown.

^b See Special Considerations for Breast Cancer in Males (Sex Assigned at Birth) (BINV-J).

Assay	Recurrence Risk/Predictive Result	Treatment Implications
Breast Cancer Index (BCI)	BCI (H/I) Low	<ul style="list-style-type: none"> For patients with T1 and T2 HR-positive, HER2-negative, and pN0 tumors, a BCI (H/I) in the low-risk range (0–5), regardless of T size, places the tumor into the same prognostic category as T1a–T1b, N0,M0. Patients with BCI (H/I) low demonstrated a lower risk of distant recurrence (compared to BCI [H/I] high) and no significant improvement in DFS or OS compared to the control arm in terms of extending endocrine therapy duration.⁸
	BCI (H/I) High	<ul style="list-style-type: none"> For patients with T1 HR-positive, HER2-negative, and pN0 tumors, a BCI (H/I) high (5.1–10) demonstrated significant rates of late distant recurrence. In secondary analyses of the MA.17, Trans-aTTom, and IDEAL trials, patients with HR-positive, T1–T3, pN0 or pN+ who had a BCI (H/I) high demonstrated significant improvements in DFS when adjuvant endocrine therapy was extended, compared to the control arm.⁸⁻¹¹ In contrast, BCI (H/I) low patients derived no benefit from extended adjuvant therapy.⁸

The NCCN also had the following to summarize about the assays mentioned above and their respective interpretations and/or rationales:

For Oncotype DX in Node-Negative, HR-positive, HER2-negative disease: “Among patients with T1b/c and T2, lymph node-negative, HR-positive, HER2-negative tumors with RS between 0-10, the risk of distant recurrence is low and these patients derive no incremental benefit from the addition of adjuvant chemotherapy to endocrine therapy. At the other end of the spectrum, patients with lymph node-negative, HR-positive, HER2-negative cancers with high RS (≥ 31) have a higher risk of distant recurrence and secondary analyses of prospective studies demonstrate a clear benefit from adjuvant chemotherapy.”

Further, “for those with intermediate RS (11-25), the recently reported TAILORx trial of postmenopausal patients (n=6711) with lymph node-negative, HR-positive, HER-2 negative breast cancer, showed similar disease-free survival rates at 9-years in those who received adjuvant chemotherapy followed by endocrine therapy compared with endocrine therapy alone.”

Based on secondary analyses, the NCCN states that for Oncotype DX in Node-Positive, HR-positive, HER2-negative disease “these results suggest that in patients with limited nodal disease (1-3 positive lymph nodes) and a low RS [< 18], the absolute benefit from chemotherapy is likely to be very small.” On the other hand,

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

“There is a clear benefit from adjuvant chemotherapy in patients with node-positive, HR-positive, HER2-negative tumors, if the RS is high (≥ 31).” However, “The absolute benefit of chemotherapy in patients with limited lymph node involvement and a RS ≤ 25 remains to be determined.”

For MammaPrint: The NCCN claims that the “data suggest that the additional benefit of adjuvant chemotherapy in patients with high-clinical risk/low genomic risk is likely to be small” and that the data suggest that “the results of the 70-gene signature do not provide evidence for making recommendations regarding chemotherapy for patients at low clinical risk.”

For PAM50: for “patients with T1 and T2, HR-positive, HER2-negative, lymph node-negative tumors, a ROR in the low range, regardless of tumor size, places the individual into the same prognostic category as T1a-T1b, N0, M0 tumors.

In patients with 1-3 lymph-node positive, HR-positive, HER2-negative disease with low-risk of recurrence score, the distant recurrence risk was less than 3.5% at 10 years with endocrine therapy alone.”

For EndoPredict: “patients with HR-positive, HER-2 negative, and lymph-node node-negative disease with a low-risk score by the 12-gene assay had risk of distant recurrence of 4% at 10 years” and “patients with T1 and T2 HR-positive, HER2-negative, and lymph node-negative tumors, a 12-gene low risk score, regardless of T size, places the tumor into the same prognostic category as T1a-T1b, N0, M0.” Citing another study, the NCCN states the following for EndoPredict: “patients with 1-3 positive nodes in the low-risk group had a 5.6% risk of distant recurrence at 10 years, suggesting that chemotherapy would be of limited benefit in these patients.”

For the BCI: “For patients with T1 and T2 HR-positive, HER2-negative, and lymph node-negative tumors, a BCI in the low-risk range, regardless of T size, places the tumor into the same prognostic category as T1a-T1b, N0, M0. There are limited data as to the role of BCI in HR-positive, HER2-negative, and lymph node-positive breast cancer” (NCCN, 2024).

The NCCN **strongly recommends (Category 1)** to consider the use of the 21-gene reverse transcriptase polymerase chain reaction (RT-PCR) assay for determining the use of adjuvant chemotherapy in patients with the following tumor characteristics:

- Hormone receptor positive.
- HER2 [human epidermal growth factor receptor 2]-negative.
- Ductal/NST, lobular, mixed or micropapillary histology.
- pT1, pT2 or pT3 stage; and pN0.
- Tumor >0.5 cm.

The assay may also be considered for pre- and postmenopausal, node-positive (up to three positive nodes) individuals if such individuals are candidates for chemotherapy.

Within a section on special considerations for breast cancer in males, the NCCN states (Category 2A), “Data are limited regarding the use of molecular assays to assess prognosis and to predict benefit from chemotherapy in males with breast cancer. Available data suggest 21-gene assay recurrence score provides prognostic information in men with breast cancer” (NCCN, 2023).

NCCN also notes that ER status should be determined for DCIS patients, but do not mention any gene expression tests for evaluation (NCCN, 2024).

National Institute for Health and Care Excellence (NICE)

NICE released three new guidelines regarding gene expression tests, which are as follows:

- “EndoPredict (EPclin score), Oncotype DX Breast Recurrence Score and Prosigna are recommended as options for guiding adjuvant chemotherapy decisions for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

negative and lymph node (LN)-negative (including micrometastatic disease; see section 5.4) early breast cancer, only if:

- they have an intermediate risk of distant recurrence using a validated tool such as PREDICT or the Nottingham Prognostic Index
 - information provided by the test would help them choose, with their clinician, whether or not to have adjuvant chemotherapy taking into account their preference.
 - the companies provide the tests to the NHS with the discounts agreed in the access proposals and
 - clinicians and companies make timely, complete and linkable record-level test data available to the National Cancer Registration and Analysis Service as described in the data collection arrangements agreed with NICE (see section 5.29).”
- MammaPrint is not recommended for guiding adjuvant chemotherapy decisions for people with ER-positive, HER2-negative and LN-negative early breast cancer because it is not cost effective (NICE, 2018).

European Society for Medical Oncology (ESMO)

ESMO notes that “In cases of uncertainty regarding indications for adjuvant chemotherapy (after consideration of other tests), gene expression assays, such as MammaPrint, Oncotype DX, Prosigna and EndoPredict, may be used, where available. These assays can determine the individual’s recurrence risk as well as potentially predict the benefit of chemotherapy”. This point was unchanged in the 2019 update (Cardoso et al., 2019; Senkus et al., 2015).”

In a 2019 update, ESMO elaborates on gene expression profiles for breast cancer. They state that “Gene expression profiles, such as MammaPrint, Oncotype DX Recurrence Score, Prosigna and Endopredict, may be used to gain additional prognostic and/or predictive information to complement pathology assessment and to predict the benefit of adjuvant chemotherapy”. They also remark that Prosigna, Endopredict, and Oncotype are intended for ER-positive early breast cancer only and that MammaPrint and OncoType are still being evaluated for clinical utility (F. Cardoso et al., 2019).

State and Federal Regulations, as applicable

Food and Drug Administration (FDA)

MammaPrint® received 510(k) clearance from the FDA on June 22, 2007. MammaPrint® is performed in Agendia laboratories and is FDA cleared for use in breast cancer patients who are under 61 years of age, with stage 1 or 2 breast cancer, tumor size ≤ 5 cm, and lymph node negative (FDA, 2007). MammaPrint® is a qualitative *in vitro* diagnostic test service which uses a 70 gene expression profile from fresh breast cancer tissue samples to assess a patient’s risk for distant metastasis (up to 10 years in patients less than 61 years of age). It is indicated for use by physicians as a prognostic marker only, along with other clinicopathological factors. On December 11, 2009, the FDA approved modifications to the cleared device, adding 5-year prognostic information for breast cancer patients ≥ 61 years of age (FDA, 2009).

On January 23, 2015, the MammaPrint® FFPE received 510(k) clearance from the FDA. It is a qualitative *in vitro* diagnostic test, using the 70 gene expression profile obtained from FFPE breast cancer tissue samples to assess a patient’s risk for distant metastasis within 5 years. Like the MammaPrint®, the MammaPrint® FFPE is performed for breast cancer patients who are under 61 years of age, with stage 1 or 2 breast cancer, tumor size ≤ 5 cm, and lymph node negative. It is indicated for use by physicians as a prognostic marker only, along with other clinicopathological factors (FDA, 2015).

The Prosigna™ Breast Cancer Prognostic Gene Signature Assay received 510(k) clearance from the FDA based on substantial equivalence to MammaPrint® on September 6, 2013. It is an *in vitro* diagnostic assay

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

performed on the NanoString nCounter® Dx Analysis System and uses formalin-fixed, paraffin embedded breast tumor tissue that has previously been diagnosed as invasive breast carcinoma. This assay measures the RNA expression profile of 58 genes and weights the expression together with clinical variables to generate a risk category and numerical score, assessing a patient's risk of distant recurrence of disease (FDA, 2013).

On August 5, 2022, FDA approved Enhertu (fam-trastuzumab-deruxtecan-nxki) for the treatment of patients with unresectable or metastatic breast cancer that is also classified as HER2-low; establishing the first FDA-approved therapy for patients diagnosed with HER2-low breast cancer.

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable service codes: 81479, 81518, 81519, 81520, 81521, 81522, 81523, 81599, 88360, 88361, 88367, 88368, 88381, 0045U, 0067U, 0153U, 0295U, S3854

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources

Agendia. (2014). *MammaPrint® FFPE Result*. <https://www.agendia.com/pdf/high-risk.pdf>

Agendia (2024b) *MammaPrint: a test to predict risk of breast cancer recurrence*. <https://www.agendia.com/our-tests/mammaprint/>

Agendia. (2024a). *Blueprint: a test to predict likely tumor behavior*. <https://www.agendia.com/our-tests/blueprint/>

Andre, F., Ismaila, N., Henry, N. L., Somerfield, M. R., Bast, R. C., Barlow, W., . . . Stearns, V. (2019). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx. *Journal of Clinical Oncology*, 37(22), 1956-1964. <https://doi.org/10.1200/JCO.19.00945>

BDRiskDx. (2023). *What is the BBDRISK DX® Test?* <https://bbdrisk.com/patients/bbdrisk-dx-test/bbdrisk-dx/>

Biotheranostics. (2023). *About Breast Cancer Index (BCI)*. <https://www.breastcancerindex.com/about-breast-cancer-index#>

Blok, E. J., Bastiaannet, E., van den Hout, W. B., Liefers, G. J., Smit, V., Kroep, J. R., & van de Velde, C. J. H. (2018). Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. *Cancer Treat Rev*, 62, 74-90. <https://doi.org/10.1016/j.ctrv.2017.10.012>

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

- Bremer, T., Whitworth, P. W., Patel, R., Savala, J., Barry, T., Lyle, S., Leesman, G., Linke, S. P., Jirstrom, K., Zhou, W., Amini, R. M., & Wärnberg, F. (2018). A Biological Signature for Breast Ductal Carcinoma in Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk. *Clin Cancer Res*, 24(23), 5895-5901. <https://doi.org/10.1158/1078-0432.Ccr-18-0842>
- Camp, N. J., Madsen, M. J., Herranz, J., Rodriguez-Lescure, A., Ruiz, A., Martin, M., & Bernard, P. S. (2019). Re-interpretation of PAM50 gene expression as quantitative tumor dimensions show utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer. *Breast Cancer Res Treat*. <https://doi.org/10.1007/s10549-018-05097-5>
- Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., . . . Senkus, E. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up dagger. *Ann Oncol*, 30(8), 1194-1220. doi:10.1093/annonc/mdz173
- Cardoso, F., van't Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., . . . Piccart, M. (2016). 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *New England Journal of Medicine*, 375(8), 717-729. <https://doi.org/10.1056/NEJMoa1602253>
- Chen, R., Xia, L., Tu, K., Duan, M., Kukurba, K., Li-Pook-Than, J., . . . Snyder, M. (2018). Longitudinal personal DNA methylome dynamics in a human with a chronic condition. *Nat Med*, 24(12), 1930-1939. <https://doi.org/10.1038/s41591-018-0237-x>
- Dabbs, D., Mittal, K., Heineman, S., Whitworth, P., Shah, C., Savala, J., Shivers, S. C., & Bremer, T. (2023). Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ. *Front Oncol*, 13, 1069059. <https://doi.org/10.3389/fonc.2023.1069059>
- Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., . . . Peto, R. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. *Lancet*, 378(9804), 1707-1716. [https://doi.org/10.1016/s0140-6736\(11\)61629-2](https://doi.org/10.1016/s0140-6736(11)61629-2)
- Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., Darby, S., . . . Peto, R. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. *Lancet*, 378(9793), 771-784. [https://doi.org/10.1016/s0140-6736\(11\)60993-8](https://doi.org/10.1016/s0140-6736(11)60993-8)
- Ding, S., Wu, J., Lin, C., Chen, W., Li, Y., Shen, K., & Zhu, L. (2019). Predictors for Survival and Distribution of 21-Gene Recurrence Score in Patients With Pure Mucinous Breast Cancer: A SEER Population-Based Retrospective Analysis. *Clin Breast Cancer*, 19(1), e66-e73. <https://doi.org/10.1016/j.clbc.2018.10.001>
- Dubsky, P. C., Singer, C. F., Egle, D., Wette, V., Petru, E., Balic, M., . . . Filipits, M. (2020). The EndoPredict score predicts response to neoadjuvant chemotherapy and neoadjuvant endocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. *Eur J Cancer*, 134, 99-106. <https://doi.org/10.1016/j.ejca.2020.04.020>
- FDA. (2007). 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY Retrieved from https://www.accessdata.fda.gov/cdrh_docs/reviews/K070675.pdf
- FDA. (2009). *MammaPrint®: 510(k) Substantial Equivalence Determination Decision Summary*. https://www.accessdata.fda.gov/cdrh_docs/reviews/K081092.pdf

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

- FDA. (2013). *Prosigna(TM) Breast Cancer Prognostic Gene Signature Assay: 510(k) Substantial Equivalence Determination Decision Summary Assay and Instrument Combination Template*. https://www.accessdata.fda.gov/cdrh_docs/reviews/K130010.pdf
- FDA. (2015). *MammaPrint® FFPE: 510(k) Substantial Equivalence Determination Decision Summary Assay and Instrument Combination Template*. https://www.accessdata.fda.gov/cdrh_docs/reviews/K141142.pdf
- Filipits, M., Dubsy, P., Rudas, M., Greil, R., Balic, M., Bago-Horvath, Z., . . . Gnant, M. (2019). Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. *Clinical Cancer Research*, *clincanres.0376.2019*. <https://doi.org/10.1158/1078-0432.CCR-19-0376>
- Filipits, M., Rudas, M., Jakesz, R., Dubsy, P., Fitzal, F., Singer, C. F., . . . Gnant, M. (2011). A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. *Clin Cancer Res*, *17*(18), 6012-6020. <https://doi.org/10.1158/1078-0432.Ccr-11-0926>
- Forouzanfar, M. H., Foreman, K. J., Delossantos, A. M., Lozano, R., Lopez, A. D., Murray, C. J., & Naghavi, M. (2011). Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. *Lancet*, *378*(9801), 1461-1484. [https://doi.org/10.1016/s0140-6736\(11\)61351-2](https://doi.org/10.1016/s0140-6736(11)61351-2)
- Foukakis, T., & Bergh, J. (2022, November 9). *Prognostic and predictive factors in early, nonmetastatic breast cancer*. <https://www.uptodate.com/contents/prognostic-and-predictive-factors-in-early-non-metastatic-breast-cancer>
- Giuliano, A. E., Connolly, J. L., Edge, S. B., Mittendorf, E. A., Rugo, H. S., Solin, L. J., Weaver, D. L., Winchester, D. J., & Hortobagyi, G. N. (2017). Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA: A Cancer Journal for Clinicians*, *67*(4), 290-303. <https://doi.org/10.3322/caac.21393>
- Gustavsen, G., Schroeder, B., Kennedy, P., Pothier, K. C., Erlander, M. G., Schnabel, C. A., & Ali, H. (2014). Health economic analysis of Breast Cancer Index in patients with ER+, LN- breast cancer. *Am J Manag Care*, *20*(8), e302-310. <https://www.ajmc.com/view/health-economic-analysis-of-breast-cancer-index-in-patients-with-er-ln-breast-cancer>
- Harnan, S., Tappenden, P., Cooper, K., Stevens, J., Bessey, A., Rafia, R., . . . Brown, J. (2019). Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. *Health Technol Assess*, *23*(30), 1-328. <https://doi.org/10.3310/hta23300>
- Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., . . . Hayes, D. F. (2016). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*, *34*(10), 1134-1150. <https://doi.org/10.1200/jco.2015.65.2289>
- Henry, N. L., Somerfield, M. R., Abramson, V. G., Ismaila, N., Allison, K. H., Anders, C. K., . . . Stearns, V. (2019). Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline. *Journal of Clinical Oncology*, *37*(22), 1965-1977. <https://doi.org/10.1200/JCO.19.00948>
- Jensen, M.-B., Lænkholm, A.-V., Balslev, E., Buckingham, W., Ferree, S., Glavicic, V., . . . Ejlertsen, B. (2020). The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

chemotherapy in high-risk breast cancer patients. *npj Breast Cancer*, 6(1), 7. <https://doi.org/10.1038/s41523-020-0148-0>

- Kalinsky, K., Barlow, W. E., Meric-Bernstam, F., Gralow, J. R., Albain, K. S., Hayes, D., . . . Puzstai, L. (2021). Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder). *Cancer Research*, 81(4 Supplement), GS3-00-GS03-00. <https://doi.org/10.1158/1538-7445.Sabcs20-gs3-00>
- Kizy, S., Huang, J. L., Marmor, S., Blaes, A., Yuan, J., Beckwith, H., . . . Hui, J. Y. C. (2018). Distribution of 21-Gene Recurrence Scores Among Breast Cancer Histologic Subtypes. *Arch Pathol Lab Med*, 142(6), 735-741. <https://doi.org/10.5858/arpa.2017-0169-OA>
- Krop, I., Ismaila, N., Andre, F., Bast, R. C., Barlow, W., Collyar, D. E., . . . Stearns, V. (2017). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. *J Clin Oncol*, Jco2017740472. <https://doi.org/10.1200/jco.2017.74.0472>
- Lashen, A., Toss, M. S., Fadhil, W., Oni, G., Madhusudan, S., & Rakha, E. (2023). Evaluation oncotype DX(®) 21-gene recurrence score and clinicopathological parameters: a single institutional experience. *Histopathology*, 82(5), 755-766. <https://doi.org/10.1111/his.14863>
- Liefers, G.-J., Noordhoek, I., Treuner, K., Putter, H., Zhang, Y., Kranenbarg, E. M. K., . . . Schnabel, C. A. (2020). Breast cancer index (BCI) predicts benefit of two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the ideal trial. *Journal of Clinical Oncology*, 38(15_suppl), 512-512. https://doi.org/10.1200/JCO.2020.38.15_suppl.512
- Ma, X.-J., Salunga, R., Dahiya, S., Wang, W., Carney, E., Durbecq, V., . . . Sgroi, D. (2008). A Five-Gene Molecular Grade Index and $HOXB13:IL17BR$ Are Complementary Prognostic Factors in Early Stage Breast Cancer. *Clinical Cancer Research*, 14(9), 2601. <https://doi.org/10.1158/1078-0432.CCR-07-5026>
- Mamounas, E. P., Tang, G., Fisher, B., Paik, S., Shak, S., Costantino, J. P., . . . Wolmark, N. (2010). Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. *J Clin Oncol*, 28(10), 1677-1683. <https://doi.org/10.1200/jco.2009.23.7610>
- Martin, M., Brase, J. C., Ruiz, A., Prat, A., Kronenwett, R., Calvo, L., . . . Rodriguez-Lescure, A. (2016). Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. *Breast Cancer Res Treat*, 156(1), 81-89. <https://doi.org/10.1007/s10549-016-3725-z>
- Myriad. (2021, 12/10/2019). *Myriad EndoPredict® Technical Specifications*. Retrieved 1/27/2020 from <https://myriad-library.s3.amazonaws.com/technical-specifications/EndoPredict-Technical-Specifications.pdf>
- Myriad. (2024a). *EndoPredict Executive Summary*. Myriad Genetics, inc. Retrieved 1/21/2020 from <https://myriad.com/managed-care/endopredict/>
- Myriad. (2024a). *EndoPredict Executive Summary*. Myriad Genetics, Inc. Retrieved 01/21/2020 from <https://myriad.com/managed-care/endopredict/>

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

- NCCN. (2024, January 25, 2024). *NCCN Clinical Practice Guidelines in Oncology; Breast Cancer v1.2024*. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
- NICE. (2018). *Tumor profiling tests to guide adjuvant chemotherapy decisions in early breast cancer*. <https://www.nice.org.uk/guidance/dg34/chapter/1-Recommendations>
- Nielsen, T. O., Parker, J. S., Leung, S., Voduc, D., Ebbert, M., Vickery, T., . . . Ellis, M. J. (2010). A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. *Clin Cancer Res*, *16*(21), 5222-5232. <https://doi.org/10.1158/1078-0432.ccr-10-1282>
- Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., . . . Wolmark, N. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med*, *351*(27), 2817-2826. <https://doi.org/10.1056/NEJMoa041588>
- Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., . . . Wolmark, N. (2006). Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol*, *24*(23), 3726-3734. <https://doi.org/10.1200/jco.2005.04.7985>
- Parker, J. S., Mullins, M., Cheang, M. C., Leung, S., Voduc, D., Vickery, T., . . . Bernard, P. S. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. *J Clin Oncol*, *27*(8), 1160-1167. <https://doi.org/10.1200/jco.2008.18.1370>
- Petkov, V. I., Miller, D. P., Howlader, N., Gliner, N., Howe, W., Schussler, N., Cronin, K., Baehner, F. L., Cress, R., Deapen, D., Glaser, S. L., Hernandez, B. Y., Lynch, C. F., Mueller, L., Schwartz, A. G., Schwartz, S. M., Stroup, A., Sweeney, C., Tucker, T. C., . . . Shak, S. (2016). Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. *npj Breast Cancer*, *2*, 16017. <https://doi.org/10.1038/npjbcancer.2016.17>
- Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M., . . . Pritchard, K. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. *Lancet*, *379*(9814), 432-444. [https://doi.org/10.1016/s0140-6736\(11\)61625-5](https://doi.org/10.1016/s0140-6736(11)61625-5)
- Poola, I., Yue, Q., Gillespie, J. W., Sullivan, P. S., Aguilar-Jakthong, J., Rao, J., Shaaban, A. M., Sauter, E. R., & Ricci, A. J. (2019). Breast Hyperplasias, Risk Signature, and Breast Cancer. *Cancer Prev Res (Phila)*, *12*(7), 471-480. <https://doi.org/10.1158/1940-6207.Capr-19-0051>
- Prat, A., Guarneri, V., Paré, L., Griguolo, G., Pascual, T., Dieci, M. V., . . . Conte, P. (2020). A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. *Lancet Oncol*, *21*(11), 1455-1464. [https://doi.org/10.1016/s1470-2045\(20\)30450-2](https://doi.org/10.1016/s1470-2045(20)30450-2)
- PreludeDx. (2024). *DCISionRT(R): Welcome to a New Paradigm for DCIS Management*. Prelude Corporation. <https://preludedx.com/physicians/>
- Qi, P., Yang, Y., Bai, Q. M., Xue, T., Ren, M., Yao, Q. L., Yang, W. T., & Zhou, X. Y. (2021). Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients. *Breast Cancer Res Treat*, *186*(2), 327-342. <https://doi.org/10.1007/s10549-020-06075-6>
- Rueda, O. M., Sammut, S.-J., Seoane, J. A., Chin, S.-F., Caswell-Jin, J. L., Callari, M., . . . Curtis, C. (2019). Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. *Nature*, *567*(7748), 399-404. <https://doi.org/10.1038/s41586-019-1007-8>

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

- Savci-Heijink, C. D., Halfwerk, H., Koster, J., Horlings, H. M., & van de Vijver, M. J. (2019). A specific gene expression signature for visceral organ metastasis in breast cancer. *BMC Cancer*, *19*(1), 333. <https://doi.org/10.1186/s12885-019-5554-z>
- Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., . . . Cardoso, F. (2015). Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, *26 Suppl 5*, v8-30. <https://doi.org/10.1093/annonc/mdv298>
- Sennerstam, R. B., Franzen, B. S. H., Wiksell, H. O. T., & Auer, G. U. (2017). Core-needle biopsy of breast cancer is associated with a higher rate of distant metastases 5 to 15 years after diagnosis than FNA biopsy. *Cancer Cytopathol*, *125*(10), 748-756. <https://doi.org/10.1002/cncy.21909>
- Sestak, I., Buus, R., Cuzick, J., Dubsy, P., Kronenwett, R., Denkert, C., . . . Dowsett, M. (2018). Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol*, *4*(4), 545-553. doi:10.1001/jamaoncol.2017.5524
- Sestak, I., Martin, M., Dubsy, P., Kronenwett, R., Rojo, F., Cuzick, J., . . . Gnant, M. (2019). Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. *Breast Cancer Res Treat*, *176*(2), 377-386. <https://doi.org/10.1007/s10549-019-05226-8>
- Shah, C., Bremer, T., Cox, C., Whitworth, P., Patel, R., Patel, A., Brown, E., Gold, L., Rock, D., Riley, L., Kesslering, C., Brown, S., Gabordi, R., Pellicane, J., Rabinovich, R., Khan, S., Templeton, S., Majithia, L., Willey, S. C., . . . Vicini, F. A. (2021). The Clinical Utility of DCISionRT® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery. *Ann Surg Oncol*, *28*(11), 5974-5984. <https://doi.org/10.1245/s10434-021-09903-1>
- Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. *CA: A Cancer Journal for Clinicians*, *69*(1), 7-34. <https://doi.org/10.3322/caac.21551>
- Silbiotech. (2021). DESCRIPTION OF THE BBDRisk Dx® TEST. In I. Silbiotech (Ed.): Silbiotech, Inc.
- Simon, R. M., Paik, S., & Hayes, D. F. (2009). Use of archived specimens in evaluation of prognostic and predictive biomarkers. *J Natl Cancer Inst*, *101*(21), 1446-1452. <https://doi.org/10.1093/jnci/djp335>
- Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., . . . Sledge, G. W., Jr. (2018). Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med*. <https://doi.org/10.1056/NEJMoa1804710>
- Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., . . . Sledge, G. W. (2015). Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. *N Engl J Med*, *373*(21), 2005-2014. <https://doi.org/10.1056/NEJMoa1510764>
- Steiling, K., & Christenson, S (2023, October 3, 2023). *Tools for genetics and genomics: Gene expression profiling*. https://www.uptodate.com/contents/tools-for-genetics-and-genomics-gene-expression-profiling?source=search_result&search=gene%20expression%20array%20cancer&selectedTitle=2~150

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

- Taghian, A., & Merajver, S.D. (2024, January 25). *Overview of the treatment of newly diagnosed, non-metastatic breast cancer*. https://www.uptodate.com/contents/overview-of-the-treatment-of-newly-diagnosed-non-metastatic-breast-cancer?source=see_link
- Toole, M. J., Kidwell, K. M., & Van Poznak, C. (2014). Oncotype dx results in multiple primary breast cancers. *Breast Cancer (Auckl)*, 8, 1-6. <https://doi.org/10.4137/bcbcr.S13727>
- Turashvili, G., Brogi, E., Morrow, M., Hudis, C., Dickler, M., Norton, L., & Wen, H. Y. (2017). The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. *Breast Cancer Res Treat*, 165(1), 65-76. <https://doi.org/10.1007/s10549-017-4326-1>
- Villarreal-Garza, C., Lopez-Martinez, E., Deneken, Z., Maffuz-Aziz, A., Muñoz-Lozano, J., Barragan-Carrillo, R., . . . Bautista, V. (2020). Change in therapeutic management after the EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients. *PLOS ONE*, 15, e0228884. <https://doi.org/10.1371/journal.pone.0228884>
- Wang, J., He, Z. Y., Dong, Y., Sun, J. Y., Zhang, W. W., & Wu, S. G. (2018). The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes. *Front Genet*, 9, 638. <https://doi.org/10.3389/fgene.2018.00638>
- Wang, W., Chen, X., Lin, L., Fei, X., Garfield, D. H., Hong, J., . . . Shen, K. (2018). Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study. *J Cancer*, 9(18), 3216-3224. <https://doi.org/10.7150/jca.27291>
- Warf, M. B., Rajamani, S., Krappmann, K., Doedt, J., Cassiano, J., Brown, K., . . . Roa, B. B. (2017). Analytical validation of a 12-gene molecular test for the prediction of distant recurrence in breast cancer. *Future Science OA*, 3(3), FSO221. <https://doi.org/10.4155/fsoa-2017-0051>
- Wärnberg, F., Karlsson, P., Holmberg, E., Sandelin, K., Whitworth, P. W., Savala, J., Barry, T., Leesman, G., Linke, S. P., Shivers, S. C., Vicini, F., Shah, C., Weinmann, S., Mann, G. B., & Bremer, T. (2021). Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS). *Cancers*, 13(23), 6103. <https://www.mdpi.com/2072-6694/13/23/6103>
- Wuerstlein, R., Kates, R., Gluz, O., Grischke, E. M., Schem, C., Thill, M., . . . Harbeck, N. (2019). Strong impact of MammaPrint and Blueprint on treatment decisions in luminal early breast cancer: results of the WSG-PRIME study. *Breast Cancer Res Treat*, 175(2), 389-399. <https://doi.org/10.1007/s10549-018-05075-x>

For Policy Titled: Gene Expression Testing for Breast Cancer Prognosis

Medical Director review 8/2019

Specialty Matched Consultant Advisory Panel 3/2020

Medical Director review 3/2020

Specialty Matched Consultant Advisory Panel 3/2021

Medical Director review 3/2021

Medical Director review 4/2021

For Policy Titled: Molecular Expression Testing for Breast Cancer Prognosis

Medical Director review 4/2022

Molecular Diagnostics for Breast Cancer Prognosis AHS - M2020

For Policy Titled: Molecular Diagnostics for Breast Cancer Prognosis

Medical Director review 4/2023

Medical Director review 4/2024

Policy Implementation/Update Information

For Policy Titled: Gene Expression Testing for Breast Cancer Prognosis

- 1/1/2019 New policy developed. BCBSNC will provide coverage for gene expression testing for breast cancer prognosis when it is determined to be medically necessary, and criteria are met. Medical Director review 1/1/2019. Policy noticed 1/1/2019 for effective date 4/1/2019. (lpr)
- 10/1/19 Reviewed by Avalon 2nd Quarter 2019 CAB. Under “When Covered” section 1: reordered and reworded bullets. Previous bullets A-I are now A-F. Deleted the coding table in Billing/Coding section as well as deleted CPT code 81400, and PLA code 00081. Added Related Policies section. Medical Director review 8/2019. (lpr)
- 10/1/19 Policy statement revised to read: BCBSNC will provide coverage for gene expression testing for breast cancer prognosis when it is determined the medical criteria and guidelines below are met. Wording revised in When Covered section. “Medically Necessary” changed to “Reimbursement is allowed...” Wording revised in the Not Covered section. “Not Medically Necessary” changed to read “Reimbursement is not allowed...” Notification given 10/1/2019 for effective date 12/2/2019. (an)
- 10/15/19 Wording in When Covered section changed from “Reimbursement is allowed...” to “is considered Medically Necessary.” Item 2 revised to read: Use of EndoPredict or PAM50 (Prosigna), to determine recurrence risk for deciding whether to undergo adjuvant chemotherapy in women with primary, invasive breast cancer with the same characteristics as considered for Oncotype DX (1A– 1I); with one exception—for individuals with 1-3 involved ipsilateral axillary lymph nodes the tests are considered investigational). Wording in the When Not Covered section changed from “Reimbursement is not allowed...” to “is considered Investigational.” Item 2 moved from this section to the revised statement in Item 2 above. Following statement is corrected to read: Use of gene expression assays in men are considered investigational. **Policy remains on notice for effective date 12/10/2019.** (an)
- 10/29/19 Wording in the Policy, When Covered, and/or Not Covered section(s) changed from Medical Necessity to Reimbursement language, where needed. (hb)
- 12/31/19 Added CPT code 81522 to Billing/Coding section for effective date 1/1/2020. (lpr)
- 2/11/20 Reviewed by Avalon Q4 2019 CAB. No changes to the policy. (lpr)
- 3/31/20 Specialty Matched Consultant Advisory Panel review 3/18/2020. No change to policy statement. (lpr)
- 5/1/20 Reviewed by Avalon 1st Quarter 2020 CAB. Clarified When covered section 1 → F to include pT1. Temporary expansion of benefit related to COVID-19 pandemic. (lpr)
- 6/2/20 Temporary expansion of benefit related to COVID-19 pandemic extended through July 31, 2020. We will reevaluate if an additional extension is needed as we approach July 31. (eel)

Molecular Diagnostics for Breast Cancer Prognosis

AHS - M2020

- 7/30/20 Temporary expansion of benefit related to COVID-19 pandemic extended through September 30, 2020. We will reevaluate if an additional extension is needed as we approach September 30. (eel)
- 9/29/20 Temporary expansion of benefit related to COVID-19 pandemic extended through December 31, 2020. We will reevaluate if an additional extension is needed as we approach December 31. (eel)
- 11/20/20 Temporary expansion of benefit related to COVID-19 pandemic extended through June 30, 2021. We will reevaluate if an additional extension is needed as we approach June 30. (eel)
- 4/6/21 Specialty Matched Consultant Advisory Panel review 3/17/2021. No change to policy statement. (lpr)
- 5/4/21 Temporary expansion of benefit related to COVID-19 pandemic removed. Medical Director review 4/20/2021. **Notification given 5/4/2021 for effective date 6/30/2021.** (bb)
- 7/1/21 Reviewed by Avalon Q1 2021 CAB. Medical Director review 4/2021. Under “When Covered” section: added coverage statement for Breast Cancer Index (BCI). Updated Description and Policy Guidelines sections. Added references. Added PLA codes 0045U, 0153U to Billing/Coding section. (lpr)
- 12/30/21 Added CPT code 81523 to Billing/Coding section for effective date 1/1/22. (lpr)

For Policy Titled: Molecular Expression Testing for Breast Cancer Prognosis

- 5/31/22 Reviewed by Avalon Q1 2022 CAB. Medical Director review 4/2022. Updated “When Covered” and “When Not Covered” sections. Updated policy guidelines and references. Added PLA codes 0067U, 0295U to Billing/Coding section. **Policy title changed from “Gene Expression Testing for Breast Cancer Prognosis” to “Molecular Expression Testing for Breast Cancer Prognosis.”** (lpr)

For Policy Titled: Molecular Diagnostics for Breast Cancer Prognosis

- 5/16/23 Reviewed by Avalon Q1 2023 CAB. Medical Director review 4/2023. Updated the following sections: description, policy guidelines and references. Deleted related policies section. Added new Note 3. Edited “When covered and when not covered” sections for clarity and reordered criteria coverage. Deleted CPT code 84999 from Billing/Coding section. **Policy title changed from “Molecular Expression Testing for Breast Cancer Prognosis” to Molecular Diagnostics for Breast Cancer Prognosis.”** (lpr)
- 5/15/24 Reviewed by Avalon Q1 2024 CAB. Medical Director review 4/2024. Added related policies section. “When covered” section edited for clarity and consistency, no change to intent and policy statement. Updated policy guidelines and references. (lpr)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.